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TP53 missense mutations significantly influence the
development and progression of various human
cancers via their gain of new functions (GOF) through
differentmechanisms. Herewe report a uniquemech-
anism underlying the GOF of p53-R249S (p53-RS), a
p53 mutant frequently detected in human hepatocel-
lular carcinoma (HCC) that is highly related tohepatitis
B infection and aflatoxin B1. A CDK inhibitor blocks
p53-RS’s nuclear translocation in HCC, whereas
CDK4 interacts with p53-RS in the G1/S phase of the
cells, phosphorylates it, and enhances its nuclear
localization. This is coupled with binding of a pep-
tidyl-prolyl cis-trans isomerase NIMA-interacting 1
(PIN1) to p53-RS, but not the p53 formwithmutations
of four serines/threonines previously shown to be
crucial for PIN1 binding. As a result, p53-RS interacts
with c-Myc and enhances c-Myc-dependent rDNA
transcription key for ribosomal biogenesis. These
results unveil a CDK4-PIN1-p53-RS-c-Myc pathway
as a novel mechanism for the GOF of p53-RS in HCC.
INTRODUCTION
The tumor suppressor p53 plays a prominent role in human
cancer prevention, as 50% of human tumors harbor mutated
TP53 (Brosh and Rotter, 2009). Among the p53 mutations, more
than 80% are missense mutations that mostly occur in p53’s
central DNA sequence-specific binding domain. There are six
hotspot mutations of p53 at R175, G245, R248, R249, R273,
and R282, identified in various primary and metastatic humanMcancers. Remarkably, these p53 mutants, besides losing their
wild-type (WT) functions and exerting their dominant-negative
(DN) effects on WT p53’s activity because p53 acts as a homote-
trameric transcriptional factor (Kern et al., 1992), can also
possess gains of new functions (GOFs) distinct from their WT
counterpart’s activity, significantly influencing the development
and progression of cancers (Brosh and Rotter, 2009).
One of the fairly studied hotspot mutants is p53-R249S
(p53-RS) (Hsu et al., 1991; Ozturk, 1991). Interestingly, p53-RS
is highly associated with hepatocellular carcinoma (HCC), which
is often diagnosed in patients with high exposure to aflatoxin B1
(AFB1) and/or infected with hepatitis virus B (HBV). To date,
p53-RS is the only hotspot mutant that has been identified
among 30% of HCCs that harbor p53 mutations (Hsu et al.,
1991; Hussain et al., 2007; Qi et al., 2015; Staib et al., 2003).
Similar to other hotspot p53 mutants, p53-RS displays both
loss of function and DN effects crucial for HCC cell proliferation
(Goh et al., 2011; Lee et al., 2012). Yet it still remains elusive if
p53-RS possesses GOF activity critical for development and
progression of HCC (Junk et al., 2008; Lee et al., 2012; Yin
et al., 1998), and if so, what would be the underlying molecular
mechanism.
In addressing these questions, we link a cell-cycle-regulated
kinase CDK4 (Lim and Kaldis, 2013), PIN1 (Lu and Zhou, 2007),
and c-Myc with the GOF activity of p53-RS by performing a set
of biochemical, molecular, and cellular studies. CDK4 plays a
key role in the cell cycle through G1/S phase by forming a com-
plex with cyclin D or A family (Johnson and Walker, 1999), acts
as an oncoprotein key for cancer cell proliferation (Sherr, 1996),
and is highly expressed in various human cancers (Malumbres
and Barbacid, 2009). PIN1 is also highly expressed in human
cancers (Yeh and Means, 2007) and plays an oncogenic role
by converting inactive oncoproteins into active ones, such as
p53 mutants (Girardini et al., 2011) or c-Myc (Farrell et al.,
2013). PIN1 binds to phosphorylated target proteins andolecular Cell 68, 1–13, December 21, 2017 ª 2017 Elsevier Inc. 1
Figure 1. CDK4 Phosphorylates p53-RS at
Ser249 in G1/S Phase and Mediates Its
Nuclear Localization
(A) The sequence comparison of p53WT and
p53RS.
(B) JNJ-7706621 (JNJ) inhibitor (Pan-CDK inhibi-
tor) blocks p53-RS’s nuclear translocation. Cell
fractions of flag-vector- or p53-RS-expressing
HEK293 stable cell were treated by JNJ (2 or
10 mM) for 16 hr or U0126 (10 mM) for 4 hr and then
harvested for WB with indicated antibodies.
(C) p53-RS interacts with CDK4 or CDK7. The
same stable cells as above were synchronizedwith
Nocodazole at 100 ng/mL for 16 hr and harvested
at different time points (different phases) for IP with
the anti-Flag antibody followed by WB with
indicated antibodies.
(D and E) CDK4 phosphorylates p53-RS in vitro.
His-p53WT or His-p53RS was purified from E.coli
for in vitro kinase reactions using Cyclin D1/CDK4
complexes commercially purchased. Phosphory-
lated proteins were detected by autoradiography
(D) or the anti-phosphor-S249 antibody (E).
(F) p53-RS is phosphorylated at G1/S phase PLC/
PRF/5 cells. PLC/PRF/5 cells were synchronized
with Nocodazole and harvested at G1/S phase for
IP with IgG or p53 antibody followed by WB with
indicated antibodies.
(G) The majority of phosphorylated p53-RS in the
nucleus. Synchronized PLC/PRF/5 cells were
harvested at G1/S phase for subcellular fraction-
ation followed by IP with IgG or the anti-p53 anti-
body followed by WB with indicated antibodies.
(H) A CDK4 inhibitor PD033291 (PD) blocks the
nuclear localization of endogenous p53-RS. PLC/
PRF/5 cells were treated with or without PD
(500 nM) for 16 hr and harvested for analysis of
subcellular fractions of endogenous p53-RS by
WB with indicated antibodies.
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isomerase activity (Lu and Zhou, 2007). Often, this modification
can mediate subcellular re-localization of target proteins (Ryo
et al., 2001). PIN1 can bind HBx to enhance hepatocarcinogen-
esis in HBV-associated hepatocytes (Datta et al., 2007). c-Myc
is a nuclear transcriptional factor essential for proliferation and
renewal of stem cells (Bouchard et al., 1998; Takahashi and
Yamanaka, 2006) and for survival of various cancer or cancer
stem cells (Gordan et al., 2007; Kim et al., 2010) partially by
activating gene expression crucial for ribosomal biogenesis
(Grandori et al., 2005), and highly expressed in 80% of human
cancers (Dang, 2012). Thus, these oncoproteins are critical for
cell proliferation and tumorigenesis.
Our studies as detailed below unveil a unique mechanism for
p53-RS’s GOF, i.e., CDK4 specifically binds to and phosphory-
lates p53-RS, and this phosphorylation facilitates PIN1 binding
and subsequent nuclear fractions of this mutant p53. In the
nucleus, p53-RS binds to and stabilizes c-Myc by blocking
FBW7-mediated degradation, consequently leading to c-Myc
activation of rDNA and tRNA transcription. Through these2 Molecular Cell 68, 1–13, December 21, 2017actions, p53-RS executes its GOF activity crucial for HCC cell
proliferation and survival.
RESULTS
CDK4 Binds to and Phosphorylates p53-RS at G1/
S Phase
As mentioned above, R249S mutation (Figures 1A and S1A) is
of high frequency in HCC and closely related to dietary
AFB1 and HBV infection. Since serine is frequently modified
with phosphorylation, and p53-RS is mostly present in the
cytoplasm, but perhaps executes its GOF in the nucleus, we
speculated that Ser249 of p53-RS could be phosphorylated,
and the phosphorylation might affect its subcellular distribution
(Gouas et al., 2010; Xu et al., 2011). To test this idea, we first
treated HEK293 cells that stably expressed exogenous
Flag-p53-RS with a pan inhibitor of CDK family kinases
(JNJ-7706621 [JNJ]) or an inhibitor of MEK1/2 (U0126). Inter-
estingly, JNJ, but not U0126, reduced the nuclear fractions of
ectopic p53-RS in the cells in a dose-dependent fashion
Figure 2. Pin1 Interacts with Ser249-Phosphorylated p53-RS
(A) Pin1 binds to mutant better than WT p53s when overexpressed in cells. WT p53 and p53-RS plasmids were co-introduced with Flag-PIN1 into H1299 cells.
Protein complexes were pulled down and detected by using coIP-WB or straight WB with indicated antibodies.
(B) Endogenous p53-RS and Pin1 interaction. PLC/PRF/5 or HepG2 cells were used for coIP with the anti-Pin1 antibody followed by WB with indicated
antibodies. Asterisk (*) indicates the light chain.
(legend continued on next page)
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responsible for this nuclear transport of p53-RS. Remarkably,
co-immunoprecipitation (coIP) assays using synchronized
HEK293 cells with expressed Flag-p53-RS showed that
CDK4 and CDK7 are co-pulled down with Flag-p53-RS,
respectively (Figure 1C). Intriguingly, CDK4 appeared to form
more complexes with p53-RS in the G1/S phase, while CDK7
appeared to do so in the G2/M phase. Since CDK7 was previ-
ously shown to phosphorylate WT p53 (Lu et al., 1997), CDK4
mainly bound to p53-RS, but not WT p53 (Figure S1B), and
since among different point mutants of p53, p53-RS formed
more complexes with CDK4 (Figure S1C), we decided to further
explore the regulation of p53-RS by this kinase here. First, we
performed IP-western blot (WB) assays using different HCC
cells, such as PLC/PRF/5 with p53-RS, Huh7 with p53-C220,
and HepG2 with WT p53. Remarkably, anti-CDK4 antibodies
pulled down much more endogenous p53-RS than p53-C220,
but none of WT p53, with CDK4 (Figure S1E), suggesting that
CDK4 might prefer to bind to p53-RS and phosphorylate it.
Indeed, CDK4 phosphorylated p53-RS, but not WT p53, in an
in vitro 32P-transfer kinase assay (Figure 1D) with Rb as a pos-
itive control (Zarkowska and Mittnacht, 1997) (Figure S1G),
which was also validated with an antibody generated specif-
ically against the phosphorylated p53-RS at S249 (Figures
1E, S1D, and S1E). The S249P250 motif of p53-RS was critical
for CDK4 phosphorylation of p53-RS, as the substitution of
P250 with alanine diminished its phosphorylation by the
CDK4/Cyclin D1 complex (Figure S1F). Consistent with this
result, CDK4/Cyclin D1 was the only kinase for p53-RS phos-
phorylation as CDK2/Cyclin A1, CDK6/Cyclin D1, and CDK4/
Cyclin D3 did not phosphorylate p53-RS in vitro (Figures S1H
and S1I). Correlated with the result in Figure 1C, p53-RS phos-
phorylation was detected in the G1/S phase of PLC/PRF/5 cells
after synchronization (Figure 1F), and knockdown of Cyclin D1,
but not Cyclin D3, in PLC/PRF/5 cells markedly reduced this
phosphorylation (Figure S1J), but the phosphorylation was
not detected in the human fibroblast-like fetal lung cell line
(Figure S1N). In line with these results, more phosphorylated
p53-RS proteins were detected in the nucleus than in the cyto-
plasm of synchronized PLC/PRF/5 cells in G1/S phase (Figures
1G and S1K), and more phosphorylation mimic mutant
p53-RDs (p53-R249D) than p53-RSs were detected in the
nuclear fraction (Figure S1L), whereas treatment of PLC/
PRF/5 cells with a specific CDK4/6 inhibitor, PD-0332991
(PD) (Rivadeneira et al., 2010), markedly reduced the nuclear(C) The schematic of the functional domains and mutated residues of p53K280-4
(D) p53K280-4MRS, but not p53K280-4M, interacts with Pin1. p53K280-4M or
complexes were pulled down and detected by using coIP-WB or straight WB wi
(E) Inhibition of phosphatases with okadaic acid (OA) leads to elevated p53-4MR
H1299 cells. Cells were treated by 1 or 5 mM OA for 1 hr before harvesting and t
(F) Dephosphorylation of p53-4MRS by CIP reduces its interaction with Pin1. p53
cells lysates were treated by CIP for 1 hr at 37C, and then used for coIP-WB or
(G) CDK4 knockdown reduces p53-4MRS interaction with Pin1. H1299 cells transf
of plasmids encoding p53-4MRS and Flag-PIN1, respectively, and harvested for
(H) CDK4 inhibitor PD reduces p53-4MRS interaction with Pin1. H1299 cells were
for 24 hr, and treated with a PD inhibitor for an additional 24 hr before being har
(I) CDK4 increases p53-4MRS interactionwith Pin1. H1299 cells were transfected
for coIP-WB or straight WB with indicated antibodies.
4 Molecular Cell 68, 1–13, December 21, 2017p53-RS level (Figure 1H). Together, these results demonstrate
that CDK4/Cyclin D1 can phosphorylate p53-RS at Ser249
in the G1/S phase, consequently leading to its nuclear
localization.
PIN1 Interaction with Ser249-Phosphorylated p53-RS Is
Dependent on CDK4
Bioinformatic analysis of p53-RS’s amino acid sequence revealed
its Ser249/Pro250 motif as a potential PIN1-binding site. To test
this possibility, we conducted a coIP assay using p53 null H1299
cells by comparing ectopic p53-RS with WT p53 as WT p53 was
shown to bind to PIN1 before (Zacchi et al., 2002; Zheng et al.,
2002). Considerably more p53-RSs than WT p53s were pulled
down with Flag-PIN1 (Figure 2A), suggesting that PIN1 prefers
binding to themutantp53overWTp53.Consistently,moreendog-
enous p53-RS-PIN1 complexes in PLC/PRF/5 cells thanWT p53-
PIN1 complexes in HepG2 were also pulled down with anti-PIN1
antibodies, and again, S249-phosphorylated p53 was detected
in the p53-PIN1 complex from PLC/PRF/5, but not HepG2, cells
(Figure 2B). Since there are four known PIN1-binding sites in p53
(Girardini et al., 2011), we compared p53-R280K-4M (S33A,
S46A, T81A, and T315A) mutants that harbor mutations at four
known PIN1-targeted residues with p53-R280K-4M-RS, whose
Arg249 is replaced with Ser (Figure 2C), in coIP assays. Remark-
ably, mutation of Arg249 to Ser enabled this PIN1-binding defec-
tive mutant p53 to bind to PIN1 efficiently (Figure 2D), indicating
that PIN1 binds to the Ser249-Pro250 site. We also generated a
p53-4M-RS with replacements of four known PIN1-targeted resi-
duesbyAla inp53-RS, similar to that in Figure 2C, and tested if this
mutant can still bind to PIN1. Indeed, this mutant p53-RS still
bound to PIN1, and this p53-4M-RS-PIN1 interaction was
enhanced by treatment with okadaic acid (OA), a non-specific
phosphatase inhibitor (Figure 2E), but eliminated by the treatment
of H1299 cell lysates with calf intestine phosphatase (CIP)
(Figure 2F). These results demonstrate that PIN1 can specifically
bind to the Ser249-Pro250 site of p53-RS highly expressed
in HCC cells, and this binding is Ser249 phosphorylation
dependent.
Next, we tested if CDK4 affects PIN1 binding to p53-RS by
conducting coIP-WB assays after either knockdown of CDK4
or treatment of H1299 cells with the CDK4 inhibitor PD after
transfection. Indeed, either knockdown of CDK4 or inhibition of
CDK4 activity by PD led to the reduction of the PIN1-p53-RS
complex level (Figures 2G and 2H). Conversely, overexpression
of CDK4 markedly increased the PIN1-p53-RS complex levelM and p53K280-4MRS.
p53K280-4MRS was co-introduced with Flag-PIN1 to H1299 cells. Protein
th indicated antibodies.
S-Pin1 association in cells. p53-4MRS was co-introduced with Flag-PIN1 into
hen used for coIP-WB or straight WB with indicated antibodies.
-4MRSs were co-introduced with Flag-PIN1 into H1299 cells. After harvesting,
WB with indicated antibodies.
ected with CDK4 or control siRNA for 24 hrwere transfected with a combination
coIP-WB or straight WB analysis with antibodies as indicated.
transfected with combinations of plasmids encoding p53-4MRS and Flag-PIN1
vested for coIP-WB or straight WB with indicated antibodies.
with a combination of plasmids encoding p53-4MRS, Flag-PIN1, and CDK4-HA
Figure 3. Nuclear Localization of Phosphor-
ylated p53-RS Is Dependent on Pin1
(A) Time-lapse analysis of GFP-p53 in H1299.
GFP-p53-RS was stably expressed in H1299 cells.
Frames show the GFP-p53-RS subcellular locali-
zation; arrows indicate theonecell division inmitosis
to two daughter cells in G1 phase. Time lapse was
30 min per frame, and t = 0 min was the first frame
markedby the arrowasobserved. Scale bar, 10mm.
The same was done for those in (B) and (C).
(B) Time-lapse analysis of GFP-p53 after treatment
with 500 nM CDK4 inhibitor (CDK4i) in H1299 cells.
(C) Time-lapse analysis of GFP-p53 after treatment
with 5 mM Pin1 inhibitor (Pin1i) in H1299 cells.
(D) Knockdown of Pin1 decreases nuclear p53-RS
level. PLC/PRF/5 cells were transfectedwith siRNA
for Pin1 (SiPin1) or p53-RS (Sip53) and used for
subcellular fractionation 72 hr after transfection,
followed by WB with indicated antibodies.
(E) Nuclear translocation of phosphorylated
p53-RS is blocked by a transport inhibitor,
Importazole. H1299 cells were transfected with a
combination of plasmids encoding p53-4MRSand/
or Flag-PIN1 and treated with Importazole over-
night before harvesting for analysis of subcellular
fractions by coIP with IgG or a p53 antibody
followed by WB with indicated antibodies.
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indicate that CDK4 can enhance PIN1 binding to p53-RS.
PIN1 Enhances p53-RS Nuclear Translocation
Our findings as shown in Figures 1, 2, and S1 suggest that CDK4
and PIN1 play a role in mediating the nuclear translocation of this
phosphorylated p53-RS. Indeed, analysis of subcellular localiza-
tion of GFP-p53-RS stably expressed in H1299 cells after treat-
ment with or without the CDK4 inhibitor PD or PIN1 inhibitor
ATRA (Wei et al., 2015) using time-lapse fluorescence showed
that GFP-p53-RS is dynamically oscillated during the cell cycle
(Figure 3), as it was localized to the nucleus in G1 phase cells
(120–150min) (Figure 3A), while evenly distributed in mitotic cells
(0–60 min) (Figure 3A). Treatment with either PD (Figure 3B) or
ATRA (Figure 3C) markedly reduced or delayed the nuclearMotranslocation of GFP-p53-RS and corre-
spondingly increased the percentage of
the cells with cytoplasmic GFP-p53-RS
(Figures S2A and S2B). Consistently,
more p53-RS molecules were detected
in the nuclear fraction in the presence of
PIN1 by WB analysis (Figure S2C). Also,
from this nuclear fraction, p53-RS was
co-pulled down with PIN1 by coIP anal-
ysis (Figure S2D), which was confirmed
by analysis of these cells in the presence
or absence of PIN1 using ImageStream
Imaging Flow Cytometer (Figures S2E–
S2G). Conversely, PIN1 knockdown
reduced the nuclear level, but not the
cytoplasmic level, of p53-RS, whileknockdown of endogenous p53-RS decreased both its own
nuclear and cytoplasmic levels (Figure 3D). Consistently,
treating the transfected H1299 cells with an importin inhibitor,
Importazole (Soderholm et al., 2011), retained most of the
phosphorylated p53-RS-PIN1 complex in the cytoplasm, but
this complex was almost exclusively detected in the nucleus
of non-treated cells that overexpressed Flag-PIN1 (Figure 3E).
These results indicate that PIN1 is required for the nuclear trans-
port of this CDK4-phosphorylated mutant p53.
p53-RS Interacts with c-Myc at G1/S Phase and
Regulates Its Stability
To determine if p53-RS affects global gene expression in HCC
cells once in the nucleus, we performed a chromatin immuno-
precipitation (ChIP)-on-chip analysis in PLC/PRF/5 cells thatlecular Cell 68, 1–13, December 21, 2017 5
Figure 4. p53-RS Interacts with c-Myc at G1/S Phase and Regulates Its Stability
(A) p53-RS binds to c-Myc at G1/S phase. Flag-vector or Flag-p53RS stably expressed HEK239 cells were synchronized as described in Figure 1C and harvested
at G1/S phase for coIP-WB or straight WB with indicated antibodies.
(B) Endogenous p53-RS binds to c-Myc at G1/S phase. PLC/PRF/5 cells were synchronized and harvested at G/S phase for coIP-WB or straight WB with
indicated antibodies.
(C) Endogenous WT p53 doesn’t bind to c-Myc. HepG2 cells were synchronized and harvested at G1/S phase for coIP-WB or straight WB with indicated
antibodies.
(D) CDK4 enhances the interaction of p53-RS with c-Myc. H1299 cells were transfected with combinations of plasmids encoding HA-c-Myc, Flag-p53-RS, or
CDK4-HA for coIP-WB or straight WB with indicated antibodies.
(E) c-Myc interacts with phosphorylated p53-RS in G1/S phase in PLC/PRF/5 cells. PLC/PRF/5 cells were synchronized and harvested at G1/S phase for
coIP-WB or straight WB with indicated antibodies.
(legend continued on next page)
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(siRNA). Interestingly, p53-RS knockdown in the cells led to
global decrease of expression of rDNA genes and genes that
encode ribosomal proteins (Figure S3A). Next, we checked if
p53-RS might regulate the expression of the genes for
ribosomal biogenesis by interacting with c-Myc. Indeed, we
detected the p53-RS-c-Myc complex by coIP-WB analysis in
Flag-p53-RS expressing HEK293 cells at the G1/S phase (Fig-
ure 4A). Consistently and interestingly, endogenous c-Myc
interacted only with p53-RS in G1/S phase in PLC/PRF/5 cells
(Figure 4B), but not with WT p53 in HepG2 cells (Figure 4C),
and the same was true for exogenous proteins (Figure S3B).
The p53-RS-c-Myc interaction was enhanced by overexpres-
sion of CDK4 (Figure 4D), but reduced by knocking down
CDK4 (Figure S3C). Also, endogenous c-Myc bound to phos-
phorylated p53-RS in G1/S phase in PLC/PRF/5 cells (Fig-
ure 4E). Interestingly, knockdown of endogenous p53-RS in
PLC/PRF/5 cells or BT-549 cells decreased c-Myc protein
level, which was rescued by a protease inhibitor MG132 (Fig-
ures 4F and S3E), suggesting that p53-RS might regulate
c-Myc’s protein level. Indeed, ectopic p53-RS increased the
half-life of endogenous c-Myc in p53 null Hep3B cells (Fig-
ure 4G). Ectopic p53-RS blocked c-Myc ubiquitination by
FBW7a (Figure S3D), a major E3 ligase for degrading c-Myc
(Yada et al., 2004), by reducing the binding of c-Myc to
FBW7a in H1299 cells (Figure 4H). Finally, the enhanced
p53-RS-c-Myc complex was not due to the increased
steady-state level of p53-RS by CDK4, as the CDK4 inhibitor
did not affect the stability of p53-RS, but reduced the half-
life of WT p53 to a certain degree (Figure S3F). Also, the
phosphorylation mimic p53-RD formed more complexes with
c-Myc than did p53-RS (Figure S3G). Altogether, these results
indicate that p53-RS binds to and stabilizes c-Myc in the G1/S
phase by preventing its FBW7a-mediated ubiquitination and
degradation.
p53-RS Increases rDNA Transcription
Next, we decided to validate some of the ChIP-on-chip data by
qPCR analysis of RNAs isolated from HCC cells with either over-
expressed or knocked down p53-RS by siRNA. Indeed, the
expression of pre-rRNA, rRNA, and tRNA was elevated by over-
expression of p53-RS in Hep3B cells (Figures 5A, 5B, S4A, and
S4B), but downregulated by knockdown of p53-RS or c-Myc in
PLC/PRF/5 cells (Figures 5C and S4C). In contrast, knockdown
of WT p53 in HepG2 cells increased the expression of pre-
rRNA and rRNA, opposite to that after knockdown of c-Myc in
the same cells (Figures 5D and S4D). Also, p53-RS co-resided
with c-Myc at c-Myc target promoters, such as rDNA or tRNA-
leu promoters, as measured by ChIP analysis (Figure 5E), and
the CDK4 inhibitor PD dramatically repressed the p53-RS activ-
ity (Figure 5F). Knockdown of p53-RS decreased the expression(F) Knockdown of p53-RS decreases the c-Myc protein level. PLC/PRF/5 cells tran
and harvested for WB analysis with indicated antibodies.
(G) p53-RS prolongs c-Myc protein half-life. The vector or p53-RS was introduced
at the time points as indicated for analysis of endogenous c-Myc proteins by WB
(H) p53-RS impairs the binding of c-Myc with FBW7a. H1299 cells were tra
4xFlag-Fbw7a, and then treated with MG132 for 4 hr before being harvested forof ribosomal protein-encoding genes at RNA levels in HCC cells
(Figure 5G), whereas overexpression of p53-RS increased their
global, though moderate, expression in HCC cells (Figure 5H).
These moderate alterations are not unexpected, as these
changes are similar to the physiological modulation of gene
expression by c-Myc (Adhikary and Eilers, 2005; Chang et al.,
2008). These results indicate that p53-RS enhances c-Myc tran-
scriptional activity and boosts up c-Myc-driven ribosomal
biogenesis.
p53-RS Renders HCC Cells More Sensitive to a CDK4
Inhibitor
To test if p53-RS plays a role in regulation of HCC cell prolifera-
tion in response to the CDK4 inhibitor PD (Rivadeneira et al.,
2010), we introduced ectopic p53-RS into p53 null Hep3B cells
and then treated them with different doses of PD. As a result,
PD treatment reduced c-Myc levels in a dose-dependent
manner in the presence of p53-RS (Figures 6A and 6B), and
also the Hep3B cells with ectopic p53-RS were more sensitive
to PD than were their parental p53 null cells (Figures 6C and
6D), as the IC50 value for cell growth inhibition decreased by
2.5-fold in the presence of p53-RS (Figure 6D). Conversely,
knockdown of p53-RS conferred resistance of PLC/PRF/5 cells
to the CDK4 inhibitor (Figures 6E–6G). Yet knockdown ofWT p53
increased proliferation of HepG2 cells without affecting the
sensitivity of the cells to a CDK4 inhibitor (Figure S5C). These
results suggest that p53-RS is a downstream player of the
CDK4 signaling in HCC cells, rendering the cells more sensitive
to the inhibitor of this kinase.
p53-RS Phosphorylation Is Correlated with HBV
Infection and High Levels of CDK4 and c-Myc in
Primary HCCs
In order to examine the clinical relevance of our findings as
shown in Figures 1, 2, 3, 4, 5, and 6, we collected primary
HCC samples from the First Affiliated Hospital of Nanchang
University in China. Our DNA sequencing analysis (Figure 7C)
identified eight of them with R249S (Figure 7A). Consistent
with previous studies (Figure S1A), HCCs harboring p53-RS
were all positive with HBV, whereas some of the selected WT
p53-containing HCCs were HBV negative (Figure S6). Also,
p53 protein levels were drastically higher in most of the eight
p53-RS HCC specimens than that in WT p53-containing HCC
samples by WB analysis (Figure 7A). In order to detect S249
phosphorylation, we enriched p53 proteins from selected
HCC samples by IP (using more proteins in WT p53-containing
HCC samples than in p53-RS-harboring HCC samples)
followed by WB with anti-phosphor-S249 antibodies. Indeed,
we detected phosphorylated S249 in four out of six p53-RS-
containing samples with high levels of p53 protein, but not in
the WT p53-containing samples, even though the p53 proteinsfected with p53 or control siRNA for 72 hr were treated with or without MG132
into Hep3B cell, and the cells were treated by CHX (100 mg/mL) and harvested
with indicated antibodies.
nsfected with combinations of plasmids encoding HA-c-Myc, p53-RS, or
coIP-WB or straight WB with indicated antibodies.
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Figure 5. p53-RS Increases c-Myc Activity
on Ribosomal Biogenesis
(A) p53-RS dramatically increases rRNA expres-
sion. Vector or p53-RS plasmid was introduced
into Hep 3B cells. RNA levels were analyzed using
RT-PCR and qPCR.
(B) p53-RS increases 5s rRNA and tRNA expres-
sion. Vector or p53-RS plasmid was introduced
into Hep 3B cells. RNA levels were analyzed using
RT-PCR and qPCR.
(C) Knockdown of p53-RS reduces rRNA expres-
sion. Sip53 or SiMyc was introduced into PLC/
PRF/5 cells that were harvested for RNA analysis
by RT-PCR and qPCR.
(D) Knockdown of WT p53 increases rRNA
expression. Sip53 or SiMyc was introduced into
HepG2 cells that were harvested for analysis of
RNA levels by RT-PCR and qPCR.
(E) p53-RS binds to c-Myc’s target promoters.
Vector or p53-RS plasmid was introduced into
Hep3B cells that were harvested for ChIP assay
using anti-p53 antibodies, and p53-RS-bound
DNAs were analyzed by qPCR.
(F) CDK4 inhibitor represses rRNA expression.
Vector or p53RSwas transfected into Hep 3B cells.
Cells were treated with 500 nM PD033291 for 24 hr
before harvesting for RNA analysis by RT-PCR and
qPCR.
(G) Knockdown of p53-RS represses the expres-
sion of mRNAs for ribosomal proteins. SiP53 was
transfected into PLC/PRF/5 cells that were har-
vested for mRNA analysis by RT-PCR and qPCR.
(H) p53-RS increases the expression of mRNAs for
ribosomal proteins. Vector or the p53-RS plasmid
was introduced into Hep 3B cells that were har-
vested for mRNA analysis by RT-PCR and qPCR.
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ures 1, 2, 3, 4, and 5, the CDK4 and c-Myc levels were also
higher in the four HCC samples (#64, #180, #74, and #79)
with S249-phosphorylated p53-RS than in those with WT or
non-S249-phosphorylated p53 (Figure 7B), consistent with the
database (Figures S5A and S5B). Also, PIN1 levels in
p53-RS-containing HCCs were moderately higher than in WT
p53-containing HCCs (Figure 7A). We also detected the
p53-RS-CDK4-c-Myc complex in the aforementioned two
pairs of p53-RS-containing HCC tumors, but not in non-p53-
RS-containing HCC samples, by coIP-WB analysis (Figure 7D).
In sum, these results in Figures 7A–7D and S6, together with
the results in Figures 1, 2, 3, 4, 5, 6, and S1–S5, demonstrate
that CDK4 mediates the activation of p53-RS by phosphory-
lating its Ser249 and enhancing its association with PIN1 and
nuclear localization, consequently boosting c-Myc-dependent
ribosomal biogenesis and cell proliferation (Figure 7E), and
in doing so, p53-RS makes HCC cells more sensitive to the
inhibition of CDK4.8 Molecular Cell 68, 1–13, December 21, 2017DISCUSSION
p53-RS is the sole hotspot mutant in
HCC (Bressac et al., 1991; Gouas
et al., 2009) and also possess GOF inpromoting HCC cell proliferation, growth, survival, and metas-
tasis (Junk et al., 2008; Yin et al., 1998). However, it has
remained completely unclear how this mutant p53 executes
these oncogenic GOF activities. Our study as presented
here shows a surprising finding that the substitution of
Arg249 with Ser in p53 converts the p53-RS into a substrate
of CDK4/Cyclin D1 in the G1/S phase of the cell cycle (Fig-
ure 1). Many tumorigenic events, including liver carcinogen-
esis, ultimately drive proliferation by impinging on CDK4
complexes in the G1 phase of the cell cycle (Asghar et al.,
2015). Also, other studies suggest that the HBV X protein
(HBx) has a role in the development of HBV-associated HCC
(Kremsdorf et al., 2006) by increasing CDK4 kinase activity
(Gearhart and Bouchard, 2010), suggesting that CDK4 plays
an important role in facilitating the development of HBV-pos-
itive HCC. Consistent with these studies, our analysis of the
TCGA genomic database also showed that the p53-RS is
highly related to amplification of CCND1, CCND2, MYC, or
CDK4 (Figure S5A), and mRNA of CDK4 is more increased
Figure 6. CDK4 Inhibitor Alleviates p53-RS-
Dependent Cell Proliferation
(A and B) p53-RS can sensitize the reduction of
c-Myc protein level by a CDK4 inhibitor, PD033291
(PD). The control or p53-RS plasmid was intro-
duced into p53 null Hep3B HCC cells. Cells were
treated by PD for 24 hr and harvested for WB with
indicated antibodies (A), and the quantification of
c-Myc protein level is shown in the graph (B).
c-Myc level was quantified against the level of
a-tubulin. AU, arbitrary unit.
(C and D) p53-RS makes Hep3B HCC cells more
sensitive to the CDK4 inhibitor PD. The control or
p53-RS plasmid was introduced into Hep3B cells.
Cells were treated by different concentrations of
PD for colony formation assay (C) or cell survival
analysis by a WST cell growth kit (D). IC50 values
are represented as mean ± SD (n = 3) (D).
(E and F) Knockdown of p53-RS makes PLC/PRF/
5 HCC cells less sensitive to the CDK4 inhibitor PD.
SiNC or Sip53 was introduced into PLC/PRF/5
cells, and cells were treated by different concen-
trations of PD for colony formation assay (E). The
quantification of colonies is shown in the graph (F).
p values were calculated for the data between
columns 1 and 3 (p = 0.0015) and between
columns 2 and 4 (p = 0.5).
(G) Cell survival analysis was also conducted in the
same set of experiments with different doses of PD
by using a WST cell growth kit. Cell survival rates
are represented as means ± SD (n = 3) for each
time point (D, day; such as 5D, 5 days). p values
were calculated as shown on top of the columns.
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estingly, p53-RS becomes a novel substrate of CDK4/Cyclin
D1, but not CDK2/Cyclin A1, CDK4/Cyclin D3, or CDK6/Cyclin
D1 (Figures 1 and S1), both in vitro and in HCC cells. It is this
CDK4/Cyclin D1-mediated phosphorylation at Ser249 that
enables p53-RS to acquire a new GOF via interaction with
PIN1 and c-Myc as described below.
Remarkably, Ser249 phosphorylation of p53-RS by CDK4
enhances its binding to PIN1 and facilitates its PIN1-dependent
nuclear localization (Figures 2, 3, and S2). Although PIN1 was
previously shown to interact with WT p53 via its Ser46-Pro47
motif or other hotspot mutant p53s via their PIN1-binding motifs
(Girardini et al., 2011; Zacchi et al., 2002), we unveiled the
Ser249-Pro250 motif as a novel binding site of PIN1, which is
dependent on CDK4 phosphorylation (Figures 2G–2I). This was
further verified by using a mutant p53 devoid of all four of the
previously identified PIN1-binding sites, as this mutant with the
substitution of Arg249 with Ser was still able to bind to PIN1Mo(Figures 2D and S2A). Also, this binding
facilitates the nuclear localization of
p53-RS, as overexpression of ectopic
PIN1 increased the nuclear fraction of
p53-RS, which was blocked by an impor-
tin inhibitor, whereas knockdown of PIN1
reduced the nuclear p53-RS level (Fig-
ure 3). Consistently, more phosphoryla-tion mimic mutant p53-RDs than p53-RSs were detected in
nuclear fractions when overexpressed in cells (Figure S1L).
Hence, our findings demonstrate that PIN1 can bind to CDK4-
phosphorylated p53-RS at the Ser249-Pro-250 motif and
mediate its nuclear transport in HCC cells.
More remarkably, four lines of evidence demonstrate that
nuclear p53-RS, but not WT p53, interacts with c-Myc in G1/S
phase cells: (1) ectopic p53-RS and c-Myc were co-immunopre-
cipitated in the G1/S phase fraction of synchronized cells
(Figure 4A); (2) endogenous and phosphorylated p53-RS in
PCL/PRF/5 cells, but not endogenous WT p53 in HepG2 cells,
formed a complex with c-Myc in G1/S phase (Figures 4B, 4C,
and 4E); (3) overexpression of CDK4 enhanced the formation of
the p53-RS-c-Myc complex (Figure 4D); and (4) p53-RS co-
residedwith c-Myc at several c-Myc target promoters (Figure 5E).
Interestingly, the p53-RS binding makes c-Myc more stable,
as knockdown of p53-RS in PLC/PRF/5 cells reduced c-Myc
protein level, which was rescued by a 26S proteasome inhibitor,lecular Cell 68, 1–13, December 21, 2017 9
Figure 7. Phosphorylation of p53-R249S Is
Well Correlated with High Levels of CDK4,
Pin1, and c-Myc in Primary Human HCCs
(A) Concurrence of high expression of p53-R249S,
c-Myc, and CDK4 in HCCs. Equal amounts of HCC
samples with or without p53-R249S were analyzed
by WB with indicated antibodies.
(B) p53-R249S is phosphorylated in HCCs. HCC
samples from (A) were subjected to IP using the
anti-p53 DO-1 followed by WB with the anti-
phosphor-S249 antibody and the rabbit mono-
clonal anti-p53 EPR17343 for total p53 protein
level (of note, equal amounts of total p53 protein
inputs were used for IP-WB for all HCC tissues
used here by increasing 5- to 6-fold more total
proteins in WT p53-containing HCCs than in
p53-RS-containing HCCs).
(C) R249S mutations were identified in HCC
specimens by TP53-Exon 7 sequencing.
(D) p53-R249Sbinds to c-Myc andCDK4 in primary
HCCs. HCC samples with or without p53-R249S
mutation were subjected to coIP-WB assays with
the anti-p53 antibody, and bound proteins were
detected by WB with indicated antibodies. The
input proteins were presented in the lower panels,
and arrowheads point to target proteins.
(E) A model for the CDK4-p53-R249S-PIN1-c-Myc
signaling pathway in HCC.
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(Figures 4F and 4G). Consistently, p53-RS reduced the binding
of c-Myc to its E3 ligase FBW7a (Figures 4H and S3D). These
results indicate that by binding to c-Myc, p53-RS protects the
former from FBW7-mediated proteolysis, leading to the increase
of c-Myc levels, and suggest that p53-RS might enhance c-Myc
transcriptional activity by stabilizing this protein, while p53-RS
could also associate with c-Myc at the latter’s target promoters
(Figure 5E), and enhancing its transcriptional activity. Indeed,
p53-RS promotes c-Myc-mediated expression of rRNA,
tRNAs, and ribosomal protein-encoding genes globally, and
consequently supports c-Myc-driven HCC cell proliferation
and survival (Figure 5). As a result, p53-RS can sensitize HCC
cells to a CDK4 inhibitor, but knockdown of endogenous p53-
RS makes the HCC cells less sensitive to this inhibitor (Figure 6).
Thus, our studies demonstrate a unique cell-cycle-regulated
signaling pathway that mediates the execution of the GOF of
p53-RS by promoting c-Myc activity once located in the nucleus
via CDK4-PIN1-involved mechanisms (Figure 7E).10 Molecular Cell 68, 1–13, December 21, 2017As previously shown (Hsu et al., 1991;
Hussain et al., 2007; Qi et al., 2015;
Staib et al., 2003), p53-RS was the
only hotspot mutation in HCC. Indeed,
our screening of 200 HCC samples
identified 8 cases with p53-RS positive
from China. Although we need to collect
more HCC samples to perform a statis-
tically significant study, this study would
take much longer time to complete, as
there are some significant differences
in terms of p53 mutation incidences inHCCs in different provinces of China (Gouas et al., 2009; Liu
et al., 2002; Qi et al., 2015) (Figure S1A). However, we did
find out that p53-RS phosphorylation at S249 is well corre-
lated with high levels of CDK4 and c-Myc in p53-RS-positive
HCC samples (Figure 7), which is in line with our HCC cellular
studies (Figures 1, 2, 3, 4, 5, and 6). These p53-RS-positive
HCCs were also well correlated with HBV infection (Figure S6).
Also, the phosphorylated p53-RS indeed formed a complex
with CDK4 and c-Myc in two pairs of p53-RS-containg HCC
tissues, but not in non-p53-RS-containing HCC samples (Fig-
ure 7D). These results are consistent with our HCC cell-based
studies above and previous studies by others, showing that
HBV infection is highly associated with CDK4 activation and
high levels of c-Myc (Ayub et al., 2013; Hansen et al., 1993;
Terradillos et al., 1997). Hence, our study using several clinical
HCC samples further verifies the concept that HBV infection
might in part help HCCs select the R249S mutation of p53
by activating CDK4 that in turn phosphorylates S249
and enhances the binding of phosphorylated p53-RS to
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Consequent PIN1 Binding, Molecular Cell (2017), https://doi.org/10.1016/j.molcel.2017.11.006PIN1, facilitating p53-RS nuclear relocation, and once in the
nucleus, phosphorylated p53-RS interacts with c-Myc and
stabilizes this transcriptional factor by inhibiting FBW7a-medi-
ated c-Myc ubiquitination and degradation, consequently
activating c-Myc and c-Myc-driven ribosomal biogenesis
and promoting cell survival (Figure 7E).
The identification of the unique CDK4-PIN1-p53-RS-c-Myc
pathway in HCC cells has two folds of biological or translational
significance. First, our findings can explain why this mutant
p53 only displays a DN function without apparent GOF in a
mouse p53R246S/R246S line (human R249S) (Lee et al., 2012).
This is probably because in the mice, p53-R246S cannot
execute its GOF by associating with c-Myc without highly active
CDK4 and/or PIN1 in their liver cells. This speculation is well in
line with the fact that the p53-RS is highly associated with
AFB1 and HBV-positive HCCs that harbor many other active
oncoproteins, such as CDK4, PIN1, or c-Myc (Chisari et al.,
1989; Jung et al., 2007; Pang et al., 2007). Also, our findings
suggest that co-targeting p53-RS with CDK4, PIN1, or c-Myc
might be more effective for anti-HCC therapy, as all these
oncoproteins are highly active in and related to HCC.
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METHOD DETAILS
Plasmids and antibodies
The V5-tagged plasmid pLenti6/V5-p53 and pLenti6/V5-p53-R249S were purchased from Addgene created by Dr. Bernard
Futscher. The Flag-p53-R249S expression plasmid was generated by point mutant from Flag/HA-p53 were gifted from Dr. Wei
Gu, using the following primers, 5-ATGGGCGGCATGAACCGGAGTCCCATCCTCA-3 and 5-TACCCGCCGTACTTGGCCTCAGGGT
AGGAGT 3. Plasmid encoding the His-tagged p53 was generated into the pET30a vector, His-p53-RS (S249S) was mutant
based on His-p53. The no-tag plasmid pcDNA3.1-p53, pcDNA3.1-p53-4M, pcDNA3.1-p53K280 and pcDNA3.1-p53K280-4M
were obtained from Dr. Giannino Del Sal, no-tag pcDNA3.1-p53-RS (S249R) and pcDNA3.1-p53-4MRS and
pcDNA3.1-p53K280-4MRS were generated by point mutant. The Flag-tagged plasmid pcDNA3.1-PIN1 was gifted frome3 Molecular Cell 68, 1–13.e1–e6, December 21, 2017
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Consequent PIN1 Binding, Molecular Cell (2017), https://doi.org/10.1016/j.molcel.2017.11.006Dr. Kunping Lu. The HA-tagged CDK4 plasmid was purchased from Addgene created by Dr. Sander van den Heuvel. The
HA-c-Myc and Flag-FBW7a plasmid were gifted from Dr. Ping Wang. Anti-Flag (Sigma-Aldrich, St. Louis, MO, USA), anti-HA
(F-7, Santa Cruz Biotechnology), anti-GFP (B-2, Santa Cruz Biotechnology), anti-p53 (DO-1, FL-393 Santa Cruz Biotechnology),
anti-p21(CP74, Neomarkers, Fremont, CA, USA), anti-PIN1 (H-123, Santa Cruz Biotechnology and #3722, Cell Signaling Technol-
ogy) anti-H3 (#4499, Cell Signaling Technology) anti-GAPDH (#5174, Cell Signaling Technology), anti-b-actin (C4, Santa Cruz
Biotechnology), CDK Antibody Sampler Kit (#9868, Cell Signaling Technology) and anti-c-Myc (ab32072, Abcam), were commer-
cially purchased. Anti-phosphor-S249 antibody was generated using a peptide GMNRp(S)PILTI-cys (NeoBioLab Cambridge,
Massachusetts, USA), and the non-phosphorylation peptide GMNRSPILTI-cys is used for blocking the non-specific signaling.
Okadaic Acid (OA) was purchased from Cell signaling technology, and alkaline phosphatase, Calf Intestinal (CIP), was purchased
from New England BioLabs. The pan CDK inhibitor JNJ-7706621 (JNJ), the MEK1/2 inhibitor U0126, the p38 MAPK inhibitor
SB203580, the PI3K inhibitor Wortmannin and the CDK4 inhibitor PD0332991 were purchased from Selleckchem. The importin
inhibitor Importazole was purchased from Sigma.
Cell culture and transient transfection
Human liver cancer cell lines HepG2, PLC/PRF/5 and Hep3B were gifted from Dr. Tong Wu at Tulane University.
The stable HKE293 cells expressing vector or Flag-p53-RSwere established byG418, the stable Hep 3B cells expressing vector or
p53-RS were infected by lenti-virus of pLenti6 vector or pLentif6-p53-RS, then established by Blasticdin.
Human cancer cell lines HepG2, PLC/PRF/5 Hep3B and H1299 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, 50 U/ml penicillin and 0.1 mg/ml streptomycinn. All cells were maintained
at 37C in a 5%CO2 humidified atmosphere. Cells seeded on the plate overnight were transfectedwith plasmids as indicated in figure
legends using the TurboFect transfection reagent by following the manufacturer’s protocol (Thermo Scientific). Cells were harvested
at 30-48h post-transfection for future experiments.
Cell fractionation
This experiment was performed as described previously (Liao et al., 2014), Briefly,106 cells were collected, washed twicewith PBS,
and resuspended in 1 mL buffer A (10 mM HEPES–KOH, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and 0.5 mM DTT) for 30 min on ice.
Phenylmethylsulfonyl fluoride was added to a final concentration of 0.2 mM, and the mixture was then Dounce homogenized until
all cytoplasmic membranes were disrupted. For cytosolic isolation, cells were centrifuged at 228 3 g for 5 min at 4C to obtain
the supernatant as cytoplasm, and pellets were washed by Buffer A twice and stored as nuclear extracts (NE).
Western blotting
Cells were harvested and lysed in lysis buffer consisting of 50mMTris/HCl (pH7.5), 0.5%Nonidet P-40 (NP-40), 1mMEDTA, 150mM
NaCl, 1mMdithiothreitol (DTT), 0.2mMphenylmethylsulfonyl fluoride (PMSF), 10 mMpepstatin A and 1mM leupeptin. Equal amounts
of clear cell lysate (20-80 mg) were used for western blotting (WB) analyses as described previously (Wang et al., 2016).
Microscopy and Image Analysis
For immunofluorescent staining, cells were fixed, stained, and mounted as described previously (Zhou et al., 2016). For live-cell
imaging, GFP-p53RS stable H1299 cells were placed on poly-L-Lysine coated glass bottom culture dishes (MatTek Corporation)
for 8–12 hr before imaging. Time-lapse microscopy was performed on an Olympus VivaView FL microscope (Louisiana Cancer
Research Center of Shared Resources of Imaging).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assay was performed using antibodies as indicated in the figure legends and described pre-
viously (Liao and Lu, 2013). The reverse cross-linked immunoprecipitated DNA fragments were purified usingGeneJET gel extraction
kit (Thermo Scientific) followed by PCR analyses for the c-Myc-responsive DNA elements on the promoters of human rDNA, E2F2
and eIF4E using the following primers, 50-AACGGTGGTGTGCGTTCCC-30 and 50-TCTCGTCTCACTCAAACCGCC-30 for human
rDNA, 50-TCACCCCTCTGCCATTAAAGG-30 and 50-AGCAGTGTATTCCCCAGGCC-30 for human E2F2, and 50-AAGCCTCTCGTT
ACTCACGC-30 and 50-AGATTCAAACCGATTGGCC-30 for eIF4E (Dai et al., 2007, 2010).
In Vitro p53-RS Ser249 Kinase Assay
The p53-RS Ser-249 kinase assay was carried out using a previously described method (Keller et al., 2001) using [g-32P]-ATP.
Substrates included 100 ng of His-p53 and 100 ng of His-p53-RS, and 1 mg of the kinase CDK4/CycD1 complex was used. Kinase
assays were also done using unlabeled ATP (1 mM) followed by SDS–PAGE, and then phosphorylated S249 was detected by WB
using the anti-p53-Ser249 antibody.
ChIP-on-chip and bioinformatics analysis
ChIPs from the PLC/PRF/5 cell lines samples were performed according to the Agilent protocol version 11.3 (https://www.agilent.
com/cs/library/usermanuals/public/G4481-90010_ChIP-on-chip_11.3.pdf), using anti-mouse IgG (sc-2025, Santa Cruz) andMolecular Cell 68, 1–13.e1–e6, December 21, 2017 e4
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School of Medicine. The bioinformatics analysis of ChIP-on-chip data were carried out by the Cancer Crusaders Next Generation
Sequence Analysis Core of the Tulane Cancer Center. Experiments were triplicate, and genes with over 1.5-fold increase in
expression (p < 0.05) were shown from the experiments. The accession number for the ChIP-on-chip reported in this paper is
GEO: GSE100968.
Immunoprecipitation
Immunoprecipitation (IP) was conducted using antibodies as indicated in the figure legends and described previously (Wang et al.,
2016). Briefly, 500 to 1000 mg of proteins were incubated with indicated antibodies at 4C for 4 h or overnight. Protein A or G
beads (Santa Cruz Biotechnology) were then added, and the mixture was left to incubate at 4C for additional 1 to 2 h. The beads
were washed at least three times with lysis buffer. Bound proteins were detected by IB with antibodies as indicated in the figure
legends.
Reverse transcription and quantitative PCR analyses
Total RNA was isolated from cells using Trizol (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s protocol. Total RNAs of
0.5 to 1mg were used as templates for reverse transcription using poly-(T)20 primers and M-MLV reverse transcriptase (Promega,
Madison,WI, USA). Quantitative PCR (Q-PCR) was conducted using SYBRGreenMix according to themanufacturer’s protocol (Bio-
Rad, Hercules, CA, USA). The primers for human p53, p21, ribosomal protein, rRNA, tRNA, and GAPDH were used as previously
described (Sun et al., 2008).
RNA interference
The siRNAs against PIN1, CDK4, c-Myc and p53 were commercially purchased. 4060nM of siRNAs were introduced into cells
using TurboFect transfection reagent following the manufacturer’s protocol. Cells were harvested 72 h after transfection for IB
or Q-PCR.
Cell viability assay
To assess the long term cell survival, the Cell Counting Kit-8 (CCK-8) (DojindoMolecular Technologies, Rockville, MD, USA) was used
according to the manufacturer’s instructions. Cell suspensions were seeded at 2,000 cells per well in 96-well culture plates at 12 h
post-transfection. Cell viability was determined by addingWST-8 at a final concentration of 10% to each well, and the absorbance of
the samples was measured at 450 nm using a Microplate Reader (Molecular Device, SpecrtraMax M5e, Sunnyvale, CA, USA) every
24 h for 4 days.
Colony formation assay
Cells were trypsinized and seeded with the same amount on 10-cm plates following siRNA transfection for 12 to 18 h. The medium
was changed every 3 days until the colonies were visible. Blasticdin was added in the mediumwhen stable cell lines were used in the
experiment. Cells were then fixed by methanol and stained by crystal violet solution at RT for 30 min. ImageJ was used for quanti-
fication of colonies.
Human Hepatocellular carcinoma specimens
Hepatocellular carcinoma (HCC) tissue samples were collected and archived at the First Affiliated Hospital of Nanchang University,
Jiangxi, China (Zhou et al., 2016). Fresh HCC cancer samples were immediately snap-frozen in liquid nitrogen and stored at 80C
until their use in. All patients provided written informed consent to participate in the study and all primary HCC samples without pre-
operative radiotherapy were included and confirmed by pathologists.
DNA sequencing for p53-RS in HCC tissues
Genomic DNA was extracted from ground HCC tissue samples. DNA was amplified by PCR to generate 110 bp product
encompassing codon 249 located at exon 7 of TP53. The primers used were: P1 50-GTTGGCTCTGACTGTACCAC-30 and
P2 50-CTGGAGTCTTCCAGTGTGAT-30. The PCR products were sequenced by GENEWIZ and aligned using NCBI BLAST
(Yang et al., 1998).
Analysis of primary HCC specimens
Equal amounts (50 mg) of total proteins from liver cancer tissues were analyzed by WB using antibodies indicated in the figure leg-
ends. As the p53-R249S levels were much higher, adjusted amounts of total proteins were used for R249S phosphorylation analysis
by IP-WB assays. Briefly, 100300 mg total proteins from R249S samples and 2000 mg total proteins from non-R249S samples were
subjected to IP analysis using themousemonoclonal anti-p53 DO-1 (Santa Cruz Biotechnology). Phosphorylation of p53-R249Swas
assessed by WB using the primary anti-phosphor-S249 antibody. The non-phosphorylation peptide GMNRSPILTI-cys was used to
block the non-specific signals before the secondary antibody was used. The total p53 proteins were determined using the rabbit
monoclonal anti-p53 EPR17343 (abcam).e5 Molecular Cell 68, 1–13.e1–e6, December 21, 2017
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Lysates of liver cancer samples were used for coIP-WB assays to determine if p53-R249S interacts with CDK4 and c-Myc in vivo.
Briefly, about 2-5 mg of total proteins were first precleared with Protein A/G beads (Santa Cruz, USA) for 30 min followed by
incubation with the anti-p53 antibody DO-1 for 4 h and Protein A/G beads for 1 h. The immunoprecipitated proteins were analyzed
by WB with the antibodies as indicated.
DATA AND SOFTWARE AVAILABILITY
The accession number for the ChIP-on-chip reported in this paper is GEO: GSE100968. Raw data have been deposited to Mendeley
Data and are available at https://doi.org/10.17632/rtzf6y82hk.1.Molecular Cell 68, 1–13.e1–e6, December 21, 2017 e6
